Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review
You may also be interested in...
Dx Departure: US FDA's Diagnostics Chief Gutierrez Steps Down
Alberto Gutierrez left FDA and government this week in a planned retirement. He was director of the office that oversees pre- and post-market programs for in vitro diagnostics and radiology devices, an office where several holes already exist in top management slots.
OIVD Becomes OIR: FDA Diagnostic Office Adds Entire Radiological Health Program
The agency has fully incorporated all of its post-market radiological health regulatory programs into its newly-named Office of In Vitro Diagnostics and Radiological Health.
OIVD Becomes OIR: FDA Diagnostic Office Adds Entire Radiological Health Program
The agency has fully incorporated all of its post-market radiological health regulatory programs into its newly-named Office of In Vitro Diagnostics and Radiological Health.